Recent Updates
Recently added Catalysts
LSTA Positive Sentiment Score: 70/100

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

Thursday, October 26, 2023 2 min read
Key Takeaway: Lisata Therapeutics, a clinical-stage pharmaceutical company, will report its third quarter 2023 financial results on November 2, 2023, followed by a conference call. The company focuses on developing therapies for advanced solid tumors and has partnerships that bolster its R&D efforts. The conference call details will be shared with registered participants, and a live webcast will also be available for broader access. Lisata anticipates announcing further clinical and business milestones in the upcoming years.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lisata Therapeutics is hosting an upcoming conference call to discuss Q3 financial results, indicating transparency and engagement with stakeholders.
  • The company is developing innovative therapies targeting advanced solid tumors, which presents potential for significant market impact.
  • Lisata has established many commercial and R&D partnerships, suggesting a robust position in the industry.

Full Press Release Details

BASKING RIDGE, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for third quarter ended September 30, 2023, on Thursday, November 2, 2023, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.
Investors and Media:
Lisata Therapeutics, Inc.
Vice President, Investor Relations and Corporate Communications
Email: jmenditto@lisata.com

Frequently Asked Questions

When will Lisata Therapeutics report its Q3 financial results?

Lisata Therapeutics will report its third quarter financial results on November 2, 2023.

What time is the conference call scheduled?

The conference call is scheduled for 4:30 p.m. Eastern time on November 2, 2023.

How can I participate in the conference call?

To participate, register via the provided link to receive call details and dial-in options.

Will the conference call be available for replay?

Yes, a replay of the call will be available two hours after its conclusion for 12 months.

What is Lisata's lead product candidate?

Lisata's lead product candidate is LSTA1, designed to enhance the delivery of anti-cancer drugs.

Tags: LSTA Viatris Investor Conferences Healthcare Lisata Therapeutics Q3 financial results advanced solid tumors CendR Platform
Last updated: Oct 26, 2023